| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisals TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus and ID1591: Belimumab for treating active autoantibody-positive systemic lupus erythematosus (review of TA397). |
|
Medicine details |
|
| Medicine name | belimumab (Benlysta®) |
| Formulation | 120 mg, 400 mg powder for concentrate for solution for infusion |
| Reference number | 599 |
| Indication | Add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus with a high degree of disease activity (e.g. positive anti-dsDNA and low complement) despite standard therapy |
| Company | GlaxoSmithKline |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/06/2011 |
| NICE guidance | TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus. |